MedTrace Logo

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

NCT04939116 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-03-23

No results posted yet for this study

Summary

The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.

Conditions

  • Glomerular Disease
  • Proteinuria

Interventions

DRUG

ANG-3070

Orally administered tyrosine kinase inhibitor capsule

DRUG

Placebo

Orally administered placebo capsule

Sponsors & Collaborators

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • John Neylan, MD · Angion Biomedica

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-24
Primary Completion
2023-07-31
Completion
2023-08-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Georgia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939116 on ClinicalTrials.gov